Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer - Report - MDSpire
Advertisement
Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer
BMI Does Not Predict Biochemical Recurrence After Radical Prostatectomy in Dutch PC Patients
Overview
This study evaluated the impact of body mass index (BMI) on clinical and pathological outcomes and biochemical recurrence (BCR) following radical prostatectomy (RP) in Dutch men with prostate cancer (PC). Results showed no significant association between BMI and adverse pathological features or risk of BCR after RP.
Background
Obesity has been proposed as a risk factor for prostate cancer development and progression, but findings remain inconsistent, particularly in European populations. Most prior studies were conducted in the US, where obesity prevalence is high. European data on the relationship between BMI and prostate cancer outcomes, including pathological features and biochemical recurrence after treatment, are limited and conflicting. This study aimed to clarify the prognostic value of BMI in a Dutch cohort undergoing RP.
Data Highlights
Characteristic
Normal Weight (BMI <25)
Overweight (BMI 25–30)
Obese (BMI ≥30)
P Value
Median Age (years)
63.3
---
---
---
Median BMI (kg/m2)
---
---
---
---
Prediagnostic PSA (ng/ml)
Lower
Intermediate
Higher
0.004
Tumor (pT) Stage
Lower
---
Higher
0.017
5-year BCR Risk (%)
30 (23–37)
32 (25–39)
25 (9–41)
0.810
Key Findings
Among 1,116 prostate cancer patients, 47% were overweight and 7% obese, with median BMI 25.3 kg/m2.
No significant differences in clinical or pathological characteristics were observed across BMI categories, except for slightly higher tumor stage and prediagnostic PSA in obese patients.
In 504 patients undergoing RP, BMI was not associated with biochemical recurrence risk over a median follow-up of 40.3 months.
The 5-year biochemical recurrence rates were similar across BMI groups: 30% (normal weight), 32% (overweight), and 25% (obese), with no statistically significant differences.
Multivariable analysis adjusting for age, PSA, Gleason score, surgical margins, and lymph node status showed BMI was not an independent predictor of biochemical recurrence.
Clinical Implications
BMI should not be considered a prognostic factor for biochemical recurrence following radical prostatectomy in Dutch men with prostate cancer. Clinicians may focus on established pathological and clinical parameters rather than BMI when assessing recurrence risk. These findings suggest that obesity may not adversely impact prostate cancer outcomes in European populations as previously hypothesized.
Conclusion
In this Dutch cohort, BMI was not predictive of adverse pathological features or biochemical recurrence after radical prostatectomy. These results do not support BMI as a useful prognostic marker for prostate cancer outcomes in European men.
References
Comprehensive Cancer Centre East, The Netherlands -- Population-based cancer registry data
Gallina et al. -- BMI and high-grade prostate cancer
German study on BMI and biochemical recurrence after RP
by Dieuwertje E. G. Kok, Joep G. H. van Roermund, Katja K. Aben, Moniek W. M. van de Luijtgaarden, Herbert F. M. Karthaus, Oncko B. van Vierssen Trip, Ellen Kampman, J. Alfred Witjes, Lambertus A. L. M. Kiemeney
Tamoxifen is commonly prescribed in hormone receptor-positive breast cancer but also associated with weight gain, which can complicate survivorship care. This narrative review summarizes evidence on tamoxifen-associated weight gain and outlines pharmacologic weight management options in this population.
